Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback